Therefore, it has been proposed that genetic variants in FOXA1 binding sites might affect ER binding to FOXA by modulating the affinity of chromatin, thereby regulating target gene expression levels and eventually contributing to the risk of breast cancer initiation and progression. Here, FOXA1 is linked to breast cancer.